Special Issues | Value-Based Cancer Care

Featured Content

Navigating Care Programs in the Post-OCM era

Since OCM ended in June of 2022, oncology practice leaders have navigated complex decisions about how to offer patients high-quality, value-driven cancer care and in which reimbursement programs they will participate.

View Content
The Future of Cancer Care Delivery

The future of cancer care delivery is shifting from fee-for-service to a value-based care approach.

View Content
Research Indicates Fewer People Understand the Link Between HPV and Certain Cancers

Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers.

View Content
Listen to our AVBCC Podcasts

Now you can take the Association for Value-Based Cancer Care (AVBCC) on the go with AVBCC podcasts. As healthcare professionals, it can be hard to find time in your busy schedule to stay up-to-date on oncology trends. Now you can receive trusted information from top industry leaders in an easy-to-listen format.

View Content

Top Trending Articles

1.

Navigating the Complex Landscape of Oral Cancer Medication

2.

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

3.

New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors

FDA Approvals, News & Updates

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma

View More Articles

Highlights from the Latest Issue: December 2023, Vol 14, No 6

December 2023, Vol 14, No 6

Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC

By William King

Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer

AVBCC Keynote: The Path to Innovation in Oncology

By Phoebe Starr

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma

Value-Based Care

Survey Shows Inflation Affecting Majority of Consumer Healthcare Decisions

Breast Reconstruction Disparities Improve Significantly with Medicaid Expansion

Walter Alexander

Innovative Technology Supports Value-Based Care Success

Amy Valley, PharmD

The Alliance for Innovation in Integrated Healthcare Provides New Forum for Stakeholders

View More Articles

Personalized Medicine | Browse By Specialty

Hematologic Malignancies

Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS

Chicago, IL—Interim results from the phase 3 COMMANDS trial demonstrated that first-line treatment with luspatercept-aamt (Reblozyl) increased hemoglobin levels and enabled nearly twice as many patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) to avoid red blood cell transfusions during the first 24 weeks of the study compared with standard-of-care epoetin alfa.

Quick Quiz: Chronic Myeloid Leukemia

Quick Quiz: Chronic Myeloid Leukemia

Chronic myeloid leukemia, also known as chronic myelogenous leukemia, is a malignancy that originates in blood-forming cells (called myeloid cells) found in bone marrow. How much do you know about chronic myeloid leukemia?

All previous special issues and supplements of Value-Based Cancer Care are available here. Browse the digital archive below or use the search page to find a specific article you're looking for.

2024

Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice

Real-World Uptake and Utilization Patterns of Biosimilars in Clinical Practice

2023

Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

Faculty Perspectives Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine

2022

2022 Year in Review - Multiple Myeloma

2022 Year in Review - Multiple Myeloma

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

Faculty Perspectives: Optimizing Clinical Outcomes and Value-Based Management in Multiple Myeloma—The Role of Isatuximab

$Interview With the Innovators Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns$

Interview With the Innovators Current Approach to the Disease Journey of Patients with Relapsed or Refractory Follicular Lymphoma: Focus on the Key Manifestations, Risk Stratification, and Management Patterns

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

Faculty Perspectives: The Evolving Clinical and Pharmacoeconomic Impact of Isatuximab in Multiple Myeloma Management

2021

MOA magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)

MOA magnifier: The Important Role of YERVOY® (ipilimumab) in Combination with OPDIVO® (nivolumab)

Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

Faculty Perspectives: Preventing and Managing Skeletal-Related Events in Cancer Patients with Bone Metastases and Multiple Myeloma

2020

Managing CCA in the Setting of COVID-19

Managing CCA in the Setting of COVID-19

2019

December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

December 2019 Highlights from the First Annual Cholangiocarcinoma Summit

2019 Fourth Annual Oncology Guide to New FDA Approvals

2019 Fourth Annual Oncology Guide to New FDA Approvals

2018

2018 Third Annual Oncology Guide to New FDA Approvals

2018 Third Annual Oncology Guide to New FDA Approvals

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnosticand Ongoing Testing Across the Care Continuum

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnosticand Ongoing Testing Across the Care Continuum

2017

June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

June 2017, Vol 8, No 3, Supplement 2: The Evolution of Chemotherapy-Induced Nausea and Vomiting Management: Challenges and Opportunities

Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma

Front-Line Treatment of Patients with Advanced Hodgkin Lymphoma

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non-Small-Cell Lung Cancer Treatment

February 2017, Vol 8, No 1, Supplement 1: Balancing Innovation and Value in Cancer Care: Spotlight on Non-Small-Cell Lung Cancer Treatment

2016

Highlights from Best Practices in Lung Cancer Navigation Summit

Highlights from Best Practices in Lung Cancer Navigation Summit

Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

Consolidation Therapy After ASCT in Hodgkin Lymphoma: Why and Who to Treat

Mechanism of Action Magnifier – 2016 Desk Reference

Mechanism of Action Magnifier – 2016 Desk Reference

Mechanism of Action: Novel Mechanisms in Lung Cancer

Mechanism of Action: Novel Mechanisms in Lung Cancer

2015

Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets

2014

Mechanism of Action: Novel Mechanisms in CINV Treatment

Mechanism of Action: Novel Mechanisms in CINV Treatment

Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer

Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer

2013

Mechanism of Action: Key Advances in Hematology Oncology

Mechanism of Action: Key Advances in Hematology Oncology

Latest Videos

Managing Cost and Patient Risk for Optimal Value-Bases Care

Managing Cost and Patient Risk for Optimal Value-Bases Care

Bringing Stakeholders Together Bringing Stakeholders Together

Bringing Stakeholders Together Bringing Stakeholders Together

View More Videos

We Want to Know